Suchergebnisse

This article presents the results of a theoretical and empirical study of the problems of the formation of information and psychological security of the personality of students and the strengthening of their social health in conditions of the intensive involvement of children and young people in the open information Internet space. The authors clarified the definition of the concept of information-psychological security as a personal neoplasm, theoretically substantiated the criteria for its formation in adolescence, substantiated the dialectical relationship between social health and information-psychological security. The results of diagnostics of personal characteristics of university students at the age of 17-19 years, which are the internal determinants of the formation of information and psychological security of the individual, are presented.

Questo lavoro analizza la 'dimensione esterna' delle politiche migratorie dell'Unione Europea e dei suoi Stati membri concentrandosi su strumenti, politiche e pratiche di cooperazione internazionale in materia di riammissione, rimpatrio e partenariato per la mobilità con Paesi terzi nell'area mediterranea. In particolare, lo scopo di questo studio è di analizzare criticamente le politiche europee e bilaterali in materia di riammissione, indagando da un lato il crescente ricorso a strumenti di cooperazione internazionale di tipo informale e di natura quasi-giuridica o politica, e dall'altro l'impatto di tali strumenti sul rispetto degli standard internazionali e sovranazionali di tutela dei diritti umani di soggetti migranti e richiedenti protezione internazionale. Questa ricerca intende esaminare se è possibile identificare un processo di 'informalizzazione' nella cooperazione internazionale in materia di riammissione nell'area mediterranea sia a livello europeo che a livello bilaterale e, in caso affermativo, quali sono le caratteristiche di questo processo e le sue implicazioni per la tutela dei diritti umani dei soggetti migranti. Il lavoro esamina, in primo luogo, lo sviluppo e le caratteristiche principali della cooperazione in materia di riammissione a livello europeo, concentrandosi sui suoi due strumenti principali: gli accordi di riammissione europei e i partenariati per la mobilità. In secondo luogo, viene esaminata la cooperazione in materia di riammissione a livello bilaterale, e in particolare tre casi studio nell'ambito delle relazioni euro-mediterranee (ovvero la cooperazione tra Italia e Libia, Spagna e Marocco, e Grecia e Turchia). Questa duplice analisi dimostra l'esistenza di un processo di 'informalizzazione multi-livello' della cooperazione internazionale in materia di riammissione, processo che emerge chiaramente non solo a livello bilaterale, ma anche a livello europeo, con la recente adozione di strumenti e sistemi di cooperazione più ampi e informali. Infine, questo lavoro analizza come il ricorso a modalità informali di cooperazione in materia di riammissione ad entrambi i livelli possa incidere negativamente sui 'diritti umani legati all'asilo' dei soggetti migranti (ovvero il principio di non-refoulement, il diritto di cercare asilo, il divieto di espulsioni collettive, e il diritto ad un ricorso effettivo), limitando la loro possibilità di ottenere protezione. ; This work analyses the external migration policy of the European Union and its Member States in the Mediterranean area, focusing on policies, instruments and practices of cooperation on readmission. In particular, the purpose of this study is to critically analyse European and bilateral readmission policies by examining the increasing use of informal quasi-legal and policy instruments of cooperation, as well as the effects that the use of such instruments may have in terms of limiting or violating migrants' human rights. This research aims to investigate whether there has been a shift towards 'informalisation' in cooperation on readmission in the Mediterranean area both at European and bilateral level, and if so, what are the features of this 'informalisation' process and its implications on migrants' human rights. Firstly, I examine the development and main features of cooperation on readmission at the European level, focusing on its two main instruments, i.e. European readmission agreements and Mobility Partnerships. Secondly, I investigate cooperation on readmission at the bilateral level, focusing on three case studies in the framework of Euro-Mediterranean relations (i.e. migration cooperation between Italy and Libya, Spain and Morocco, Greece and Turkey). This analysis demonstrates the existence of a process of 'multi-level informalisation' of cooperation on readmission, which has clearly emerged not only at the bilateral level but also at the European level, with the recent adoption of broader and more informal frameworks of cooperation. Finally, this work analyses how informal modalities of cooperation on readmission at both levels may impact on the 'asylum-related human rights' of migrants (i.e. the principle of non-refoulement, the right to seek asylum, the prohibition of collective expulsion, the right to an effective remedy), limiting their possibility to access protection.

Several susceptibility loci for classical Hodgkin lymphoma have been reported. However, much of the heritable risk is unknown. Here, we perform a meta-analysis of two existing genome-wide association studies, a new genome-wide association study, and replication totalling 5,314 cases and 16,749 controls. We identify risk loci for all classical Hodgkin lymphoma at 6q22.33 (rs9482849, P = 1.52 × 10-8) and for nodular sclerosis Hodgkin lymphoma at 3q28 (rs4459895, P = 9.43 × 10-17), 6q23.3 (rs6928977, P = 4.62 × 10-11), 10p14 (rs3781093, P = 9.49 × 10-13), 13q34 (rs112998813, P = 4.58 × 10-8) and 16p13.13 (rs34972832, P = 2.12 × 10-8). Additionally, independent loci within the HLA region are observed for nodular sclerosis Hodgkin lymphoma (rs9269081, HLA-DPB1*03:01, Val86 in HLA-DRB1) and mixed cellularity Hodgkin lymphoma (rs1633096, rs13196329, Val86 in HLA-DRB1). The new and established risk loci localise to areas of active chromatin and show an over-representation of transcription factor binding for determinants of B-cell development and immune response. ; In the United Kingdom, Bloodwise (LLR; 10021) provided principal funding for the study. Support from Cancer Research UK (C1298/A8362 supported by the Bobby Moore Fund) and the Lymphoma Research Trust is also acknowledged. A.S. is supported by a clinical fellowship from Cancer Research UK. For the UK-GWAS, sample and data acquisition were supported by Breast Cancer Now, the European Union and the Lymphoma Research Trust. The UK-GWAS made use of control genotyping data generated by the WTCCC. We acknowledge use of genotype data from the British 1958 Birth Cohort DNA collection, which was funded by the Medical Research Council Grant G0000934 and the Wellcome Trust Grant 068545/Z/02. A full list of the investigators who contributed to the generation of the data is available from http://www.wtccc.org.uk. Funding for this project was provided by the Wellcome Trust under awards 076113 and 085475. Patients for the new GWAS were ascertained through the National Study of Hodgkin Lymphoma Genetics (http://www.public.ukcrn.org.uk) and we thank the HighThroughput Genomics Group at the Wellcome Trust Centre for Human Genetics (funded by Wellcome Trust grant reference 090532/Z/09/Z) for the generation of Genotyping data. The BCAC study would not have been possible without the contributions of the following: Manjeet K. Bolla, Qin Wang, Kyriaki Michailidou and Joe Dennis. BCAC is funded by Cancer Research UK (C1287/A10118, C1287/A16563). For the BBCS study, we thank Eileen Williams, Elaine Ryder-Mills, Kara Sargus. The BBCS is funded by Cancer Research UK and Breast Cancer Now and acknowledges NHS funding to the National Institute of Health Research (NIHR) Biomedical Research Centre (BRC) and the National Cancer Research Network (NCRN). We thank the participants and the investigators of EPIC (European Prospective Investigation into Cancer and Nutrition). The coordination of EPIC is financially supported by the European Commission (DGSANCO) and the International Agency for Research on Cancer. The national cohorts are supported by: Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF) (Germany); the Hellenic Health Foundation, the Stavros Niarchos Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Cancer Research UK (14136 to EPIC-Norfolk; C570/ A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom). We thank the SEARCH and EPIC teams, which were funded by a programme grant from Cancer Research UK (C490/A10124) and supported by the UK NIHR BRC at the University of Cambridge. We thank Breast Cancer Now and the Institute of Cancer Research (ICR) for support and funding of the UKBGS, and the study participants, study staff, and the doctors, nurses and other health-care providers and health information sources who have contributed to the study. We acknowledge NHS funding to the Royal Marsden/ICR NIHR BRC. UKGPCS would like to thank The Institute of Cancer Research and The Everyman Campaign for funding support. The UKGPCS acknowledges The Prostate Cancer Research Foundation, Prostate Action, The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI), the NIHR funding to the NIHR Biomedical Research data managers and consultants for their work in the UKGPCS study and urologists and other persons involved in the planning, and data collection of the CAPS study. Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) (U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I). Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher). The PRACTICAL consortium was supported by Cancer Research UK Grants C5047/ A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, European Commission's Seventh Framework Programme grant agreement no. 223175 (HEALTH-F2-2009-223175), and The National Institute of Health (NIH) Cancer PostCancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative). We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. The APBC BioResource, which form part of the PRACTICAL consortium, consists of the following members: Wayne Tilley, Gail Risbridger, Renea Taylor, Judith A Clements, Lisa Horvath, Vanessa Hayes, Lisa Butler, Trina Yeadon, Allison Eckert, Pamela Saunders, Anne-Maree Haynes, Melissa Papargiris. At the MRC University of Glasgow Centre for Virus Research, funding was provided by Leukaemia Lymphoma Research (12022). The Scotland and Newcastle Epidemiological Study of Hodgkin Disease (SNEHD) was funded by the Kay Kendall Leukaemia Fund and the Young Adult Hodgkin Case–Control Study (YHCCS) and the Epidemiology and Cancer Statistics Group Lymphoma Case–Control Study (ELCCS) were funded by Bloodwise. German funding was provided by the German Cancer Aid, the Harald Huppert Foundations, The German Federal Ministry of Education and Research (eMed, Cliommics 01ZX1309B), the Multiple Myeloma Research Foundation, the Heinz Nixdorf Foundation (Germany), the Ministerium für Innovation, Wissenschaft und Forschung des Landes NordrheinWestfalen and the Faculty of Medicine University Duisburg–Essen. For their help with UK sample collection we thank Hayley Evans, James Griffin, Joanne Micic, Susan Blackmore, Beverley Smith, Deborah Hogben, Alison Butlin, Jill Wood, Margot Pelerin, Alison Hart, Katarzyna Tomczyk and Sarah Chilcott-Burns

Several susceptibility loci for classical Hodgkin lymphoma (cHL) have been reported, however much of the heritable risk is unknown. Here, we perform a meta-analysis of two existing genome-wide association studies (GWAS), a new GWAS, and replication totalling 5,314 cases and 16,749 controls. We identify risk loci for all cHL at 6q22.33 (rs9482849, P=1.52 × 10-8) and for nodular sclerosis HL (NSHL) at 3q28 (rs4459895, P=9.43 × 10-17), 6q23.3 (rs6928977, P=4.62 × 10-55 11), 10p14 (rs3781093, P=9.49 × 10-13), 13q34 (rs112998813, P=4.58 × 10-8) and 16p13.13 (rs34972832, P=2.12 × 10-8). Additionally, independent loci within the HLA region are observed for NSHL (rs9269081, HLA-DPB1*03:01, Val86 in HLA-DRB1) and mixed cellularity HL (rs1633096, rs13196329, Val86 in HLA-DRB1). The new and established risk loci localise to areas of active chromatin and show an over-representation of transcription factor binding for determinants of B-cell development and immune response. ; In the United Kingdom, Bloodwise (LLR; 10021) provided principal funding for the study. Support from Cancer Research UK (C1298/A8362 supported by the Bobby Moore Fund) and the Lymphoma Research Trust is also acknowledged. A.S. is supported by a clinical fellowship from Cancer Research UK. For the UK-GWAS, sample and data acquisition were supported by Breast Cancer Now, the European Union and the Lymphoma Research Trust. The UK-GWAS made use of control genotyping data generated by the WTCCC. For further information, please visit the publishr's website.